Our Science

Elcella was born from over two decades of combined research at the Wingate Institute of Neurogastroenterology (Queen Mary University of London). Our founders have transitioned from mapping the fundamental neurobiology of the gut to developing targeted metabolic interventions.

• Dr. Madusha Peiris, PhD: A Senior Lecturer in Enteric Neurobiology, Dr. Peiris is a leading authority on nutrient-sensing GPCRs and gut-brain communication. Her seminal work, published in Gut, redefined the distal intestine as a primary endocrine organ rather than a passive site of absorption..
• Dr. Rubina Aktar, PhD: An Honorary Researcher in appetite regulation, Dr. Aktar’s expertise lies in human tissue platforms and enteric neuroscience. Her research, featured in the British Journal of Pharmacology, characterised GPR84 as a "metabolic gatekeeper" linking dietary lipids to hormonal output.

2. The Satiety Signal Deficit in Obesity

In healthy physiology, the gut acts as a sophisticated sensory organ. However, clinical data confirms that in individuals with obesity, this sensory-hormonal axis is compromised.

• The Hormonal Gap: Research by Dr Madusha defined the effect of obesity on neurtient receptor expression and setiety hormone expression, reporting significantly lower postprandial secretion of PYY (Peptide YY) and GLP-1.
• The Consequence: This diminished signal leads to reduced satiety, increased hunger, and a failure of the "ileal brake"—the mechanism that naturally slows gastric emptying.

3. Precision Mapping: The L-Cell Geography

Elcella’s efficacy is rooted in the "Spatial Sensing" discovery. Conventional nutrition assumes the stomach and small intestine handle all nutrient signaling. Our research overturned this, mapping a high density of Enteroendocrine L-cells in the distal ileum and colon.

• Distal Density: We identified that nutrient-sensing GPCRs—specifically GPR84 (sensing medium-chain fatty acids) and FFAR4 (sensing long-chain fatty acids)—increase in expression in the Lower Gut.
• The Synergy Effect: Our preclinical data shows that activating both GPR84 and FFAR4 simultaneously creates a synergistic effect, more than doubling the release of GLP-1 and PYY compared to single-receptor activation.
• The "Control Hub": By targeting the lower intestine, Elcella engages the body’s most potent satiety hub, which remains largely under-stimulated by modern, highly processed diets that are absorbed too proximally.

4. The Clinical Efficacy: A Physiological Bypass

Elcella is a patented, nutrient-based formulation that replicates the metabolic benefits of gastric bypass surgery through a non-invasive, oral delivery system.

Coming soon

Dosing & Administration

Elcella is engineered as a physiological catalyst, designed to lower the "biological friction" of weight management by enhancing native satiety signals. For optimal clinical outcomes, practitioners should follow the stratified two-phase protocol to reactivate and maintain the gut-brain axis.

1. Patient Selection & Contraindications
To ensure the efficacy of the pH-dependent delivery system and patient safety, the following criteria must be observed:

• Gastrointestinal Surgical History: Excluded due to altered transit times and pH gradients, which may compromise the precision delivery of the bioactive nutrients to the distal colon.
• Synthetic Incretin Mimetics: Elcella is not recommended for concurrent use with GLP-1 or GIP agonists (e.g., Semaglutide, Tirzepatide). Combining these therapies may create a super-additive, supraphysiological load, increasing the risk of nausea or gastroparesis-like symptoms.
• Pregnancy & Pediatrics: Not recommended for pregnant or breastfeeding women due to increased metabolic demands, nor for individuals under 18 years of age.

2. The Elcella Clinical Protocol

The protocol is divided into two distinct phases to first upregulate and then stabilize endogenous hormone release.

• Duration: Phase 1 requires a minimum of 12 weeks of consistent use to achieve physiological adaptation.
• Dosing Lead-Time: Administer doses 2–4 hours before main meals or peak craving periods to allow for gastrointestinal transit to the colon.
• Spacing: Ideally, space the two daily doses approximately 5 hours apart (e.g., 10:00 AM and 3:00 PM).

3. Administration Guidelines

To protect the integrity of the targeted delivery technology:

• Integrity: Capsules must be swallowed whole; do not chew or open.
• Hydration: Administer each dose with 250ml of water to facilitate rapid gastric transit.
• Flexibility: Can be taken with or without food.

4. Synergistic Lifestyle Integration

Elcella provides the biological support needed to adhere to dietary interventions that were previously unsustainable due to persistent "food noise".

Mindful Eating & Nutrition

• Portion Management: Because Elcella reduces caloric intake by approximately 12% per meal, clinicians should advise patients to proactively serve 20% less food than usual.
• Behavioral Interruption: Implement a 20-minute pause between the first sensation of hunger and eating to differentiate homeostatic hunger from hedonic cravings.
• Dietary Matrix: Prioritise prebiotic vegetables (artichokes, leeks) to support L-cell health, lean proteins to preserve muscle mass, and resistant starches (oats, cooled potatoes) that ferment in the large intestine.

Movement Protocols

• Post-Prandial Walking: A 10-minute walk after main meals to attenuate glycemic excursions and support insulin sensitivity.
• Resistance Training: Recommended to ensure weight loss is driven by adipose tissue reduction rather than lean muscle mass loss.

Recommending Elcella

Elcella should be framed as a drug-free intervention that repairs the biological "satiety deficit" found in obesity by reactivating the gut’s own hormonal signaling.

1. Identifying the Ideal Patient

Elcella is particularly effective for patients in the following clinical scenarios:

• Targeting Visceral Fat: Ideal for patients with a history of central adiposity. Our consumer trials observed a 7cm reduction in waist circumference over 12 weeks, suggesting a significant impact on visceral fat—the metabolically active fat surrounding internal organs. These changes often manifest in body recomposition and reduced waist size before significant shifts are seen on the scale.
• The Transitioning Patient: Those tapering off synthetic GLP-1 injections who need a "soft landing" to prevent "food noise" rebound and weight regain.
• The Side-Effect Sensitive Patient: Individuals who cannot tolerate the nausea, vomiting, or gastrointestinal distress associated with supraphysiological doses of synthetic mimetics.
• The Maintenance-Focused Patient: Those at their goal weight seeking a sustainable, long-term protocol to preserve weight loss through natural appetite regulation.
• The "Injection Ineligible" Group: Elcella is a viable option for patients who are medically ineligible for synthetic GLP-1 injections due to history of gallbladder issues or pancreatic concerns.
• Contraindicated Groups (Standard Safety): We do not recommend Elcella for patients with a history of major GI surgery (bypasses, resections) or those currently using GLP-1 injections.

2. Clinical Talking Points

When discussing Elcella with patients, use the following framework to explain its "Deep Science" simply:

• Zero Medication Interference: As a targeted food supplement, Elcella does not interact with systemic medications. It can be safely integrated into protocols involving statins, blood thinners, HRT, and antidepressants.
• Localised Action: Unlike drug treatments that circulate throughout the entire body, Elcella’s active mechanism is localised to the colonic mucosa, triggering the "colonic brake" without systemic load.
• "Awakening" the Colon: Explain that obesity often leaves the "fullness cells" in the lower gut underactive. Elcella uses a patented "delivery vehicle" to reach these specific cells and turn them back on.
• Natural vs. Synthetic: Note that while injections replace hormones with lab-made versions, Elcella prompts the body to release its own natural cocktail (GLP-1 and PYY), mirroring the body's healthy, post-meal rhythm.
• The Commitment: Emphasise that Elcella is not a "quick fix" but a biological retraining. Consistent daily use of the Awaken Protocol for at least 12 weeks is required to achieve steady-state hormonal signaling.

"You Can Do It Yourself"

When explaining the science to patients, focus on biological empowerment:

• Restoration vs. Replacement: Synthetic GLP-1 injections are a replacement—they introduce a lab-made analog to take over your body’s job. Elcella is restorative; it provides the specific nutrient keys to unlock your own biological potential.
• Natural Rhythm: While injections keep hormone levels artificially high, Elcella prompts your body to release its own natural cocktail (GLP-1 and PYY) in sync with your meals.
• Biological Retraining: Emphasize that Elcella is a journey of retraining the gut-brain axis. Consistent daily use of the Awaken Protocol is required to achieve and maintain hormonal steady-state signaling.

3. Setting the Success Formula

To maximise outcomes, recommend integrating Elcella with the following behavioral shifts:

• The 20-Minute Pause: Advise patients to wait 20 minutes before snacking to allow the endogenous satiety signals to reach the brain.
• Proactive Portioning: Since Elcella reduces hunger by ~12%, patients should serve themselves 20% less food than their "usual" portion to align with their new satiety levels.
• Nutrient Synergy: Encourage a diet rich in prebiotic fibers and lean proteins to provide the necessary substrate for healthy L-cell function.

Patient Support

At Elcella, we believe that biological intervention is most effective when paired with compassionate, consistent support. We want every patient to feel empowered and informed, viewing their weight management not as a struggle, but as a guided restoration of their natural health.

A Partnership, Not an Afterthought
We provide a support ecosystem that ensures patients never feel they are navigating their metabolic health alone. As an affiliate, you can reassure your patients that Elcella provides:

• Journey-Led Guidance: Patients who opt-in at checkout receive a series of supportive emails designed to explain the physiological changes occurring in their gut and what to expect in the coming weeks.
• Direct Access to Expertise: We offer complimentary 1:1 support sessions and calls with Elcella specialists and scientists to review progress and answer deep-science questions.
• Real-Time Assistance: Our team is available via email and WhatsApp (Mon–Fri, 9–5) with same-day response goals, ensuring patients feel confident and heard throughout their journey.

Key Pillars for Clinical Support
When supporting your patients, aligning with Elcella’s core messaging helps maintain the "biological steady-state" required for success:

1. Emphasise Consistency over Intensity

• Steady-State Signaling: Remind patients that unlike acute drugs, Elcella works by consistently "awakening" native L-cells.
• The 12-Week Horizon: Encourage patients to stay the course for the full 12-week Awaken Protocol, as sporadic use will not achieve the required signaling for effective appetite regulation.

2. Approach with Sensitivity and Empathy

• Biological, Not Behavioral: Frame hunger as a "satiety signal deficit" rather than a lack of willpower.
• Lowering Friction: Explain that Elcella is designed to lower "physiological friction," making healthy choices feel more natural and less like a constant battle.

3. Encourage Mindful Integration

• Celebrate Small Wins: Focus on "non-scale victories," such as a 20% reduction in portion sizes or a decrease in "food noise".
• Supportive Habits: Gently guide patients toward synergistic habits like post-meal walks and choosing "slow-release" prebiotic carbohydrates.

Patient Success

Success with Elcella is not always measured by the scale alone. Because Elcella works by retraining the biological gut-brain axis, clinicians should monitor a variety of physiological and behavioral markers that indicate the mechanism is active—often weeks before a significant reduction in body mass is observed.

Patient Monitoring: Signs of Efficacy
Clinicians should look for these key indicators that the Elcella mechanism is successfully upregulating endogenous hormone release:

Immediate Digestive Shifts: A Sign of Activation
It is not uncommon for users to experience immediate digestive changes, such as looser stools or occasional constipation. While we aim for maximum comfort, these shifts are actually a positive clinical sign—they confirm the formula has reached the colon and is successfully interacting with the gut microbiome and L-cells.

• A Sign of Efficacy: Any "gut reaction" typically indicates that the targeted nutrients are actively engaging the distal signaling pathways.
• These issues are usually acute and short-lived as the body adapts to the new nutrient exposure.
• Managing Comfort: If a patient is worried or uncomfortable, advise them to "start slow" or drop their dosage temporarily.
  • Recommended Titration: Moving to 2 capsules twice daily and gradually increasing to the full dose (4 capsules twice daily) over two weeks usually resolves sensitivity.
  • Hydration is Key

Behavioral & Appetitive Shifts

• Alteration of Snack Preference: A distinct shift away from hyper-palatable, high-sugar/high-fat foods is a primary sign of efficacy, linked to GPR120 (FFAR4) signaling modulation of fat taste perception.
• Cessation of Cravings: Patients often report a "quieting of food noise," indicating successful saturation of the gut-brain satiety signaling pathway.
• Increased Thirst: An indirect marker of hormonal activation; the upregulation of PYY alters fluid transport, and patients should be advised to increase water intake.

Anthropometric & Somatic Changes

• Body Recomposition: Patients may report clothes fitting looser despite a static scale weight, often indicating a shift in body composition (loss of visceral adipose tissue) or a reduction in systemic inflammation.
• Dermatological Improvements: Clinicians may observe improvements in skin barrier function, hydration, and hair texture due to the high-quality bioactive fatty acids in the formulation.
• Immunomodulatory Observations: Anecdotal reports suggest a reduction in allergic reactivity, supported by evidence that enteroendocrine cells orchestrate mucosal immunity.

Cognitive and Emotional Stability

• Neurodivergent Management: Patients with ADHD or OCD may report more manageable traits due to stabilised glucose variance and regulated gut-derived neurotransmitter signaling.
• Improved Mood and Reduced Fatigue: Stabilised energy levels are frequently reported, attributed to blood glucose stabilisation and optimised gut-brain axis signaling.

Troubleshooting / FAQs

Q: The patient has missed several doses. How should they proceed?

A: Resume the standard protocol as soon as possible. Do not "double up" to compensate for missed days if it exceeds the maximum daily tolerance (8 capsules). Emphasise to the patient that Elcella relies on consistent stimulation of colonic L-cells to maintain steady-state hormone signaling. Sporadic adherence will result in sub-optimal outcomes.

Q: The patient is reporting new gastrointestinal issues (loose stools/cramping) since starting.

A: This is likely a transient response of the colonic microbiome interacting with the new exposure to nutrients. Action: Reduce to half dose (4 capsules a day) or 2 capsules a day if persistent. Gradually increase dosing over 5–7 days as tolerance develops. Ensure capsules are taken with sufficient water to facilitate digestive processes and colonic transit.

Q: The patient is not seeing any weight or appetite changes after 4 weeks.

A: Physiological adaptation varies between individuals; advise the patient to continue consistently for a minimum of 6 weeks as the retraining of the gut-brain axis is cumulative. Concurrently, clinicians should review the patient's specific lifestyle factors—particularly meal and snack times—to re-optimise their dosing schedule, ensuring doses are taken 2–4 hours prior to key mealtimes or craving windows to account for the necessary colonic transit time. Finally, verify "Lifestyle Integration" by ensuring the patient is prioritizing fiber and protein and actively using behavioral techniques like the 20-minute pause, rather than relying solely on passive appetite suppression.

Q: The patient complains of post-prandial bloating or abdominal discomfort.

A: This is often a result of slower gastric emptying mediated by increased GLP-1 and PYY, whereby larger habitual eating volumes can lead to excessive fullness. Action: The patient is likely eating their "old" portion size and needs to be advised to proactively reduce serving sizes by 20%. Eating a large volume meal while gastrointestinal transit is slowed will inevitably lead to distension and discomfort.

Q: I want to switch from injectables to Elcella, how do I do this?

A: We recommend waiting 7 days after the final dose before starting Elcella. This allows the synthetic medication to clear, so Elcella can begin re-training the gut’s natural signaling pathways.

Q: How can you access Elcella?

A: Patients can access Elcella through their clinic. It can also be purchased online through the Elcella website, which is currently live in the UK and US.